Characterization of monoclonal antibodies against GRIM-19, a novel IFNβ and retinoic acid-activated regulator of cell death

Journal of Interferon and Cytokine Research

Volumn 22, Issue 10, 2002, Pages 1017-1026

  Hu, Jiadi ^a   Angell, Jon E ^a   Zhang, Jun ^a   Ma, Xinrong ^a   Seo, Taegun ^b   Raha, Abhijit ^a   Hayashi, Jun ^c   Choe, Joonho ^b   Kalvakolanu, Dhananjaya V ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON REGULATORY FACTOR 1; MONOCLONAL ANTIBODY; ONCOPROTEIN; REGULATOR PROTEIN; RETINOIC ACID; RETINOID INTERFERON INDUCED MORTALITY 19 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BIOLOGICAL RESPONSE MODIFIER; GRIM19 PROTEIN, HUMAN; GRIM19 PROTEIN, MOUSE; NUCLEAR PROTEIN; OXIDOREDUCTASE; RECOMBINANT PROTEIN;

ARTICLE; CANCER CELL DESTRUCTION; CELL DEATH; CELL NUCLEUS; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; ANIMAL; APOPTOSIS; CELL CULTURE; CELL STRAIN 3T3; DRUG EFFECT; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; MOUSE; MOUSE MUTANT; TUMOR SUPPRESSOR GENE;

ANIMALIA;

3T3 CELLS; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIOLOGICAL RESPONSE MODIFIERS; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HUMANS; INTERFERON-BETA; MICE; MICE, MUTANT STRAINS; NADH, NADPH OXIDOREDUCTASES; NUCLEAR PROTEINS; RECOMBINANT PROTEINS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0036440556     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999002760624242     Document Type: Article

References (59)

1. Korsmeyer, S.J. (1999). Bcl-2 gene family and the regulation of programmed cell death. Cancer Res. 59, 1693s-1700s.
2. Ashkenazi, A., and Dixit, V.M. (1998). Death receptors: Signaling and modulation. Science 281, 1305-1308.
3. Thornberry, N.A., and Lazebnik, Y. (1998). Caspases: Enemies within. Science 281, 1312-1316.
4. Leist, M., and Jaattela, M. (2001). Four deaths and a funeral: From caspases to alternative mechanisms. Nat. Rev. Mol. Cell. Biol. 2, 589-598.
5. Kalvakolanu, D.V., and Borden, E.C. (1996). An overview of the interferon system: Signal transduction and mechanisms of action. Cancer Invest. 14, 25-53.
6. Kalvakolanu, D.V. (2000). Interferons and cell growth control. Histol. Histopathol. 15, 523-537.
7. Hong, W.K., and Itri, L.M. (1994). Retinoids and human cancer. In: The Retinoids: Biology, Chemistry and Medicine. M.B. Sporn, A.B. Roberts, and D.S. Goodman (eds.) New York: Raven Press, pp. 597-630.
8. Evans, T.R., and Kaye, S.B. (1999). Retinoids: Present role and future potential. Br. J. Cancer 80, 1-8.
9. Mangelsdorf, D.J., and Evans, R.M. (1995). The RXR heterodimers and orphan receptors. Cell 83, 841-850.
10. Lotan, R., Dawson, M.I., Zou, C.C., Jong, L., Lotan, D., and Zou, C.P. (1995). Enhanced efficacy of combinations of retinoic acid- and retinoid X receptor-selective retinoids and alpha-interferon in inhibition of cervical carcinoma cell proliferation. Cancer Res. 55, 232-236.
11. Sun, S.Y., Yue, P., Wu, G.S., El-Deiry, W.S., Shroot, B., Hong, W.K., and Lotan, R. (1999). Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 18, 2357-2365.
12. Thacher, S.M., Vasudevan, J., and Chandraratna, R.A. (2000). Therapeutic applications for ligands of retinoid receptors. Curr. Pharm. Des. 6, 25-58.
13. Sporn, M.B., and Suh, N. (2000). Chemoprevention of cancer. Carcinogenesis 21, 525-530.
14. Mader, S., Leroy, P., Chen, J.Y., and Chambon, P. (1993). Multiple parameters control the selectivity of nuclear receptors for their response elements. Selectivity and promiscuity in response element recognition by retinoic acid receptors and retinoid X receptors. J. Biol. Chem. 268, 591-600.
15. Moore, D.M., Kalvakolanu, D.V., Lippman, S.M., Kavanagh, J.J., Hong, W.K., Borden, E.C., Paredes-Espinoza, M., and Krakoff, I.H. (1994). Retinoic acid and interferon in human cancer: Mechanistic and clinical studies. Semin. Hematol. 31, 31-37.
16. Lindner, D.J., Borden, E.C., and Kalvakolanu, D.V. (1997). Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin. Cancer Res. 3, 931-937.
17. Hofmann, E.R., Boyanapalli, M., Lindner, D.J., Weihua, X., Hassel, B.A., Jagus, R., Gutierrez, P.L., and Kalvakolanu, D.V. (1998). Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol. Cell. Biol. 18, 6493-6504.
18. Deiss, L.P., and Kimchi, A. (1991). A genetic tool used to identify thioredoxin as a mediator of a growth inhibitory signal. Science 252, 117-120.
19. Angell, J.E., Lindner, D.J., Shapiro, P.S., Hofmann, E.R., and Kalvakolanu, D.V. (2000). Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J. Biol. Chem. 275, 33416-33426.
20. Jayachandra, S., Low, K.G., Thlick, A.E., Yu, J., Ling, P.D., Chang, Y., and Moore, P.S. (1999). Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF dement by using different transcription coadaptors. Proc. Natl. Acad. Sci. USA 96, 11566-11571.
21. Harlow, E., and Lane, D. (1988). Antibodies: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
22. Gao, S.J., Boshoff, C., Jayachandra, S., Weiss, R.A., Chang, Y., and Moore, P.S. (1997). KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 15, 1979-1985.
23. Resnitzky, D., Tiefenbrun, N., Berissi, H., and Kimchi, A. (1992). Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells. Proc. Natl. Acad. Sci. USA 89, 402-406.
24. Choubey, D., Li, S.J., Datta, B., Gutterman, J.U., and Lengyel, P. (1996). Inhibition of E2F-mediated transcription by p202. EMBO J. 15, 5668-5678.
25. Choubey, D., and Gutferman, J.U. (1997). Inhibition of E2F4/DP-1-stimulated transcription by p202. Oncogene 15, 291-301.
26. Datta, B., Li, B., Choubey, D., Nallur, G., and Lengyel, P. (1996). p202 an interferon-inducible modulator of transcription, inhibits transcriptional activation by the p53 tumor suppressor protein, and a segment from the p53-binding protein 1 that binds to p202 overcomes this inhibition. J. Biol. Chem. 271, 27544-27555.
27. Tanaka, N., Ishihara, M., Lamphier, M.S., Nozawa, H., Matsuyama, T., Mak, T.W., Aizawa, S., Tokino, T., Oren, M., and Taniguchi, T. (1996) Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature 382, 816-818.
28. Tanaka, N., Ishihara, M., Kitagawa, M., Harada, H., Kimura, T., Matsuyama, T., Lamphier, M.S., Aizawa, S., Mak, T.W., and Taniguchi, T. (1994). Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77, 829-839.
29. 0-like arrest. Mol. Cell. Biol. 16, 3934-3944.
30. Melamed, D., Tiefenbrun, N., Yarden, A., and Kimchi, A. (1993). Interferons and interleukin-6 suppress the DNA-binding activity of E2F in growth-sensitive hematopoietic cells. Mol. Cell. Biol. 13, 5255-5265.
31. Der, S.D., Yang, Y.L., Weissmann, C., and Williams, B.R. (1997). A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc. Natl. Acad. Sci. USA 94, 3279-3283.
32. Zhou, A., Paranjape, J., Brown, T.L., Nie, H., Naik, S., Dong, B., Chang, A., Trapp, B., Fairchild, R., Colmenares, C., and Silverman, R.H. (1997). Interferon action and apoptosis are defective in mice devoid of 2′, 5′-oligoadenylate-dependent RNase L. EMBO J. 16, 6355-6363.
33. Ghosh, A., Sarkar, S.N., Rowe, T.M., and Sen, G.C. (2001). A specific isozyme of 2′-5′-oligoadenylate synthetase is a dual function pro-apoptotic protein of the Bcl-2 family. J. Biol. Chem. 276, 25447-25455.
34. Chow, W.A., Fang, J.J., and Yee, J.K. (2000). The IFN regulatory factor family participates in regulation of Fas ligand gene expression in T cells. J. Immunol. 164, 3512-3518.
35. Kirchhoff, S., Sebens, T., Baumann, S., Krueger, A., Zawatzky, R., Li-Weber, M., Meinl, E., Neipel, F., Fleckenstein, B., and Krammer, P.H. (2002). Viral IFN-regulatory factors inhibit activation-induced cell death via two positive regulatory IFN-regulatory factor 1-dependent domains in the CD95 ligand promoter. J. Immunol. 168, 1226-1234.
36. Nakayama, M., Kayagaki, N., Yamaguchi, N., Okumura, K., and Yagita, H. (2000). Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J. Exp. Med. 192, 1373-1380.
37. Kayagaki, N., Yamaguchi, N., Nakayama, M., Eto, H., Okumura, K., and Yagita, H. (1999). Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189, 1451-1460.
38. Sedger, L.M., Shows, D.M., Blanton, R.A., Peschon, J.J., Goodwin, R.G., Cosman, D., and wiley, S.R. (1999). IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J. Immunol. 163, 920-926.
39. Wang, Q., Ji, Y., Wang, X., and Evers, B.M. (2000). Isolation and molecular characterization of the 5′-upstream region of the human TRAIL gene. Biochem. Biophys. Res. Commun. 276, 466-471.
40. Gong, B., and Almasan, A. (2000). Genomic organization and transcriptional regulation of human Apo2/TRAIL gene. Biochem. Biophys. Res. Commun. 28, 747-752.
41. Toomey, N.L., Deyev, V.V., Wood, C., Boise, L.H., Scott, D., Liu, L.H., Cabral, L., Podack, E.R., Barber, G.N., and Harrington, W.J., Jr. (2001). Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene 20, 7029-7040.
42. Chawla-Sarkar, M., Leaman, D.W., and Borden, E.C. (2001). Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: Correlation with TRAIL/apo21 induction in melanoma cell lines. Clin. Cancer Res. 7, 1821-1831.
43. Meng, R.D., and El-Deiry, W.S. (2001). p53-independent upregulafion of KILLER/DR5 TRAIL receptor expression by glucocorficoids and interferon-gamma. Exp. Cell Res. 262, 154169.
44. Liu, Y., Lee, M.O., Wang, H.G., Li, Y., Hashimoto, Y., Klaus, M., Reed, J.C., and Zhang, X. (1996). Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol. Cell. Biol. 16, 1138-1149.
45. Pfitzner, E., Kirfel, J., Becker, P., Rolke, A., and Schule, R. (1998). Physical interaction between retinoic acid receptor and the oncoprotein myb inhibits retinoic acid-dependent transacfivation. Proc. Natl. Acad. Sci. USA 95, 5539-5544.
46. Peidrafita, F.J., and Pfahl, M. (1997). Retinoid-induced apoptosis and Spl cleavage occur independently of transcription and require caspase activation. Mol. Cell. Biol. 17, 6348-6358.
47. Ruggero, D., Wang, Z.G., and Pandolfi, P.P. (2000). The puzzling multiple lives of PML and its role in the genesis of cancer. Bioessays 22, 827-835.
48. Lin, R.J., Egan, D.A., and Evans, R.M. (1999). Molecular genetics of acute promyelocytic leukemia. Trends Genet. 15, 179-184.
49. Wang, Z.G., Delva, L., Gaboli, M., Rivi, R., Giorgio, M., Cordon-Cardo, C., Grosveld, F., and Pandolfi, P.P. (1998). Role of PML in cell growth and the retinoic acid pathway. Science 279, 1547-1551.
50. Chelbi-Alix, M.K., Pelicano, L., Quignon, F., Koken, M.H., Venturini, L., Stadler, M., Pavlovic, J., Degos, L., and De The, H. (1995). Induction of the PML protein by interferons in normal and APL cells. Leukemia 9, 2027-2033.
51. Nason-Burchenal, K., Gandini, D., Botto, M., Allopenna, J., Seale, J.R., Cross, N.C., Goldman, J.M., Dmitrovsky, E., and Pandolfi, P.P. (1996). Interferon augments PML and PML/RAR alpha expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid-resistant promyelocytic cell line. Blood 88, 3926-3936.
52. Chelbi-Alix, M.K., Quignon, F., Pelicano, L., Koken, M.H., and De The, H. (1998). Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J. Virol. 72, 1043-1051.
53. Gongora, C., David, G., Pintard, L., Tissot, C., Hua, T.D., Dejean, A., and Mechti, N. (1997). Molecular cloning of a new interferon-induced PML nuclear body-associated protein. J. Biol. Chem. 272, 19457-19463.
54. Kolla, V., Weihua, X., and Kalvakolanu, D.V. (1997). Modulation of interferon action by retinoids. Induction of murine Stat1 gene expression by retinoic acid. J. Biol. Chem. 272, 9742-9748.
55. Gianni, M., Terao, M., Fortino, I., Licalzi, M., Viggiano, V., Barbui, T., Rambaldi, A., and Garattini, E. (1997). Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood 89, 1001-1012.
56. Matikainen, S., Ronni, T., Lehtonen, A., Sareneva, T., Melen, K., Nordling, S., Levy, D.E., and Julkunen, I. (1997). Retinoic acid induces signal transducer and activator of transcription (Stat) 1, Stat2, and p48 expression in myeloid leukemia cells and enhances their responsiveness to interferons. Cell Growth Differ. 8, 687-698.
57. Chidambaram, N.V., Angell, J.E., Ling, W., Hofmann, E.R., and Kalvakolanu, D.V. (2000). Chromosomal localization of human GRIM-19, a novel IFN-beta and retinoic acid-activated regulator of cell death. J. Interferon Cytokine Res. 20, 661-665.
58. Gao, A.C., Lou, W., Ichikawa, T., Denmeade, S.R., Barrett, J.C., and Isaacs, J.T. (1999). Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2. Prostate 38, 46-54.
59. Fearnley, I.M., Carroll, J., Shannon, R.J., Runswick, M.J., Walker, J.E., and Hirst, J. (2001). GRIM-19, a cell death regulatory gene product, is a subunit of bovine mitochondrial NADH: Ubiquinone oxidoreductase (complex I). J. Biol. Chem. 276, 38345-38348.